Mara Goldstein
Stock Analyst at Mizuho
(2.76)
# 1,436
Out of 4,667 analysts
73
Total ratings
42.59%
Success rate
7.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $10.06 | +218.09% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $14.28 | +194.12% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $24.10 | +107.47% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $15.60 | +188.46% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $70.39 | +9.39% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.60 | +169.23% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $2.07 | +286.47% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $2.58 | +365.12% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $8.24 | +264.08% | 4 | Sep 15, 2023 | |
| VSTM Verastem | Reiterates: Buy | $36 | $3.93 | +816.03% | 5 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $1.01 | +494.06% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $8.94 | -60.85% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.32 | +3,650.00% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $2.11 | +847.87% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $99.86 | +30.18% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $0.87 | +130.81% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.84 | +322.54% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.64 | +1,313.76% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $47.67 | -58.04% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.33 | +658.29% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.22 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.12 | +173.44% | 1 | Oct 12, 2017 |
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $10.06
Upside: +218.09%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $14.28
Upside: +194.12%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $24.10
Upside: +107.47%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $15.60
Upside: +188.46%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $70.39
Upside: +9.39%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.60
Upside: +169.23%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $2.07
Upside: +286.47%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $2.58
Upside: +365.12%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $8.24
Upside: +264.08%
Verastem
Aug 29, 2023
Reiterates: Buy
Price Target: $36
Current: $3.93
Upside: +816.03%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $1.01
Upside: +494.06%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $8.94
Upside: -60.85%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.32
Upside: +3,650.00%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $2.11
Upside: +847.87%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $99.86
Upside: +30.18%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $0.87
Upside: +130.81%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.84
Upside: +322.54%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.64
Upside: +1,313.76%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $47.67
Upside: -58.04%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.33
Upside: +658.29%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $26.22
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.12
Upside: +173.44%